Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in ...
Only 21.7% of more than 318 000 women initiated systemic hormone therapy (HT) within 12 months of a natural menopause ...
TMS 2026: Stephanie Faubion, MD, on how to identify overlooked menopause symptoms and guide hormonal or nonhormonal treatment ...
Stephanie Faubion, MD, on how to identify overlooked menopause symptoms and guide hormonal or nonhormonal treatment decisions ...
Maki, PhD, explains that OPTION-VMS provided reassuring news about the safety of fezolinetant (Veozah): No new or emerging ...
Women who reported more frequent physical activity experienced significantly lower perimenopause symptom burden across ...
JoAnn Pinkerton, MD: Elinzanetant is a dual neurokinin receptor inhibitor. It's an NK1 and NK3 receptor antagonist, and what ...
OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and ...
Women receiving menopause hormone therapy (HT) alongside semaglutide experienced significantly greater weight loss than those ...
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use. Postmenopausal women using hormone therapy had ...
Long-acting cabotegravir and lenacapavir both deliver near-complete protection. The faculty compare dosing schedules, drug interactions, and injection site reactions, and share techniques that make ...
Pauline Maki, PhD, discusses real-world OPTION-VMS data linking fezolinetant to improvements in menopausal VMS, depression, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results